Business Context and Reporting Period
This Form 8-K Current Report was filed by Alto Neuroscience, Inc. (ANRO) on March 11, 2024, covering events occurring on March 8, 2024. The filing addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel appointments and associated compensation arrangements.
Material Changes
The primary material change reported is the appointment of Maha Radhakrishnan, M.D., to the Board of Directors and the Nominating and Corporate Governance Committee (NCGC). Dr. Radhakrishnan, previously the Group Senior Vice President and Chief Medical Officer at Biogen, Inc., was appointed as a Class I director with a term expiring at the 2025 Annual Meeting of Stockholders. The Board determined she is independent under NYSE and SEC rules.
Guidance, Outlook, and Compensation Details
There is no forward-looking guidance, outlook, or discussion of risks and contingencies in this filing. The document details the compensatory arrangements for the new director:
- Initial Option Grant: 30,574 shares of common stock, vesting in equal monthly installments over three years.
- Annual Option Grant: 15,287 shares of common stock, vesting on the earlier of the first anniversary of the grant date or the next annual stockholder meeting.
- Cash Retainer: $40,000 annually for Board service plus $5,000 annually for NCGC service, payable in quarterly installments.
- Indemnification: A standard indemnification agreement was executed to protect Dr. Radhakrishnan for liabilities arising from her affiliation with the Company.
Investor Verification Checklist
- Verify the independence status of Dr. Maha Radhakrishnan under current NYSE listing standards.
- Review the total number of outstanding options granted to non-employee directors to assess potential dilution.
- Confirm the vesting schedule and exercise terms of the initial 30,574 share option grant.
- Check for any subsequent filings regarding the impact of this appointment on the composition of the Nominating and Corporate Governance Committee.